Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg SPfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg SPfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S

Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S

No trades
See on Supercharts

Key facts today


Pfizer's Q3 revenue was $16.65 billion, down 5.9% year-on-year. Adjusted EPS was $0.87, exceeding estimates. Full-year revenue outlook is $61-$64 billion, with EPS forecast of $3-$3.15.
Pfizer raised its Metsera bid to $8.1 billion amid competition from Novo Nordisk's $10 billion offer. Pfizer is pursuing legal action to uphold their merger agreement.
Pfizer's earnings reports are currently under scrutiny by investors, reflecting ongoing interest in the company's financial performance amid recent market activity.
Analyze the impactAnalyze the impact
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪121.73 B‬EUR
1.60EUR
‪7.75 B‬EUR
‪61.46 B‬EUR
‪5.68 B‬
Beta (1Y)
0.53
Employees (FY)
‪81 K‬
Change (1Y)
‪−7 K‬ −7.95%
Revenue / Employee (1Y)
Net income / Employee (1Y)

About Pfizer, Inc.


CEO
Albert Bourla
Website
Headquarters
New York
Founded
1849
ISIN
CA7170651060
FIGI
BBG015CD5H66
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Check out other big names from the same industry as PFEB.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Displays a symbol's price movements over previous years to identify recurring trends.
XS173899459
Pfizer Inc. 2.735% 15-JUN-2043
Yield to maturity
5.71%
Maturity date
Jun 15, 2043
P
PFE5588844
Pfizer Investment Enterprises Pte. Ltd. 5.34% 19-MAY-2063
Yield to maturity
5.68%
Maturity date
May 19, 2063
P
PFE5588843
Pfizer Investment Enterprises Pte. Ltd. 5.3% 19-MAY-2053
Yield to maturity
5.57%
Maturity date
May 19, 2053
US717081ED1
Pfizer Inc. 4.125% 15-DEC-2046
Yield to maturity
5.47%
Maturity date
Dec 15, 2046
US717081EV1
Pfizer Inc. 4.0% 15-MAR-2049
Yield to maturity
5.46%
Maturity date
Mar 15, 2049
US717081DE0
Pfizer Inc. 4.3% 15-JUN-2043
Yield to maturity
5.43%
Maturity date
Jun 15, 2043
US717081FA6
Pfizer Inc. 2.7% 28-MAY-2050
Yield to maturity
5.41%
Maturity date
May 28, 2050
US717081EK5
Pfizer Inc. 4.2% 15-SEP-2048
Yield to maturity
5.41%
Maturity date
Sep 15, 2048
P
PFE5588591
Pfizer Investment Enterprises Pte. Ltd. 5.11% 19-MAY-2043
Yield to maturity
5.38%
Maturity date
May 19, 2043
US717081DK6
Pfizer Inc. 4.4% 15-MAY-2044
Yield to maturity
5.27%
Maturity date
May 15, 2044
PFE4297191
Pfizer Inc. 5.6% 15-SEP-2040
Yield to maturity
5.24%
Maturity date
Sep 15, 2040

See all PFEB bonds 

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S stocks are traded under the ticker PFEB.
PFEB reached its all-time high on Jan 15, 2009 with the price of 104.45 EUR, and its all-time low was 6.05 EUR and was reached on Apr 9, 2025. View more price dynamics on PFEB chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S financials in yearly and quarterly reports right on TradingView.
Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S is going to release the next earnings report on Feb 3, 2026. Keep track of upcoming events with our Earnings Calendar.
PFEB earnings for the last quarter are 0.74 EUR per share, whereas the estimation was 0.54 EUR resulting in a 37.52% surprise. The estimated earnings for the next quarter are 0.58 EUR per share. See more details about Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S earnings.
Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S revenue for the last quarter amounts to ‪14.19 B‬ EUR, despite the estimated figure of ‪14.06 B‬ EUR. In the next quarter, revenue is expected to reach ‪15.41 B‬ EUR.
PFEB net income for the last quarter is ‪2.45 B‬ EUR, while the quarter before that showed ‪2.74 B‬ EUR of net income which accounts for −10.70% change. Track more Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S financial stats to get the full picture.
No, PFEB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2025, the company has ‪81 K‬ employees. See our rating of the largest employees — is Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S EBITDA is ‪21.80 B‬ EUR, and current EBITDA margin is 36.93%. See more stats in Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S financial statements.
Like other stocks, PFEB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S stock right from TradingView charts — choose your broker and connect to your account.